Table 3 Patients’ prognoses with different combination regimen and follow-up time.
Combination regimen | Follow-up time | No. of included study | No. recurrence/total (%) | No. disease-free case/total (%) | No. progression/total (%) | No. death from any causes/total (%) | No. death from bladder cancer/total (%) | No. severe side-effects/total (%) |
|---|---|---|---|---|---|---|---|---|
Combination regimen 1 | Medium-term (2–5 yrs) | 4 | 43/146 (29.5) | 53/96 (55.2) | 1/75 (1.3) | 3/23 (13) | 0/50 | 0/75 |
Combination regimen 2 | Short-term (≤2 yrs) | 5 | 49/221 (22.2) | 103/146 (70.5) | 6/181 (3.3) | 1/181 (0.6) | 0/221 | 3/221 (1.4) |
Medium-term (2–5 yrs) | 5 | 84/321 (26.2) | 145/233 (62.2) | 14/292 (4.8) | 32/233 (13.7) | 5/292 (1.7) | 23/321 (7.2) | |
Long-term (≥5 yrs) | 2 | 89/209 (42.6) | 94/209 (45) | 16/209 (7.7) | 79/209 (37.8) | 9/209 (4.3) | 5/209 (2.4) | |
Combination regimen 3 | Short-term (≤2 yrs) | 1 | 0/20 | — | 0/20 | — | 0/20 | 0/20 |
Medium-term (2–5 yrs) | 5 | 136/314 (43.3) | 154/314 (49) | 39/314 (12.4) | 2/155 (1.3) | 13/314 (4.1) | 16/314 (5.1) | |
Long-term (≥5 yrs) | 1 | 19/28 (67.9) | — | 8/28 (28.6) | 20/28 (71.4) | 8/28 (28.6) | — | |
Combination regimen 4 | Short-term (≤2 yrs) | 1 | 1/21 (4.8) | — | — | — | 0/21 | 0/21 |
Long-term (≥5 yrs) | 1 | 44/211 (20.9) | — | 26/211 (12.3) | 51/211 (24.2) | 10/211 (4.7) | 20/211 (9.5) |
